Disease severity assessment
Disease severity was assessed by EASI score at timepoint 1 (either
assessed during face-to-face visit or the last recorded EASI score in
patient’s file) and at timepoint 3, being performed if dermatology units
restored their regular outpatient clinical activity. At timepoint 2, due
to sanitary restriction, no EASI score was reported. In addition,
patient-reported evaluations included: 0-10 NRS for pruritus intensity
(itch-NRS), sleep disturbances/sleeplessness by a 0-10 NRS scale
(sleep-NRS), self-evaluated AD severity by a 0-10 NRS scale (AD-NRS),
self-evaluation of patient’s AD clinical course (patient perception of
“AD status”, defined as stable/no flaring, improved, or worsened,
during the observation period), and ongoing treatment. Details about
treatment interruption or suspension were recorded. Data on SARS-CoV-2
swab testing, hospitalization, clinical outcomes of COVID-19 disease,
and quarantine due to close contact to COVID-9 patients were also
collected.